Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

T Cell Types and Functions01:24

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Inflammatory Bowel Disease III: Crohn's Disease01:25

Inflammatory Bowel Disease III: Crohn's Disease

Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...
Inflammatory Bowel Disease II: Ulcerative Colitis01:20

Inflammatory Bowel Disease II: Ulcerative Colitis

Ulcerative colitis is a chronic inflammatory disorder of the colon characterized by continuous mucosal inflammation that typically begins in the rectum and extends proximally in a uniform pattern. Its pathogenesis involves a complex interplay of genetic predisposition, immune dysregulation, and environmental influences. These factors converge to impair the colon’s epithelial defenses and promote an exaggerated inflammatory response against luminal contents.Breakdown of the Mucosal BarrierA...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Preclinical development of AMG 139, a human antibody specifically targeting IL-23.

British journal of pharmacology·2014
Same author

Are Th17 cells in the gut pathogenic or protective?

Mucosal immunology·2011
Same author

Radium and roentgen therapy in the treatment of menopausal uterine bleeding.

American journal of obstetrics and gynecology·2010
Same author

Adolescent primigravida.

Surgery, gynecology & obstetrics·2010
Same author

Extended haplotypes and linkage disequilibrium in the IL1R1-IL1A-IL1B-IL1RN gene cluster: association with knee osteoarthritis.

Genes and immunity·2004
Same author

Aquaporin 5-deficient mouse lungs are hyperresponsive to cholinergic stimulation.

Proceedings of the National Academy of Sciences of the United States of America·2001
Same journal

Targeting the ischemic cascade: Review on approved and investigational stroke therapies.

Current opinion in pharmacology·2026
Same journal

Senotherapeutic strategies for ovarian aging: Mechanistic insights and translational perspectives.

Current opinion in pharmacology·2026
Same journal

Chrono-immunotherapy in precision oncology: Circadian control of the tumor microenvironment and time-of-day optimization of immune checkpoint blockade.

Current opinion in pharmacology·2026
Same journal

Methotrexate: Integrating molecular pharmacology, systems toxicology, and precision rescue strategies.

Current opinion in pharmacology·2026
Same journal

Acupuncture and non-invasive neuromodulation-induced neuro-endocrine-immune changes associated with the amelioration of depression-like behaviors: A systematic review of animal studies.

Current opinion in pharmacology·2026
Same journal

Alopecia areata: Mechanisms, targeted therapies, and translational challenges.

Current opinion in pharmacology·2026
See all related articles

Related Experiment Video

Updated: May 24, 2026

Lymphocyte Isolation from Human Skin for Phenotypic Analysis and Ex Vivo Cell Culture
10:31

Lymphocyte Isolation from Human Skin for Phenotypic Analysis and Ex Vivo Cell Culture

Published on: April 8, 2016

IL-36 in psoriasis.

J E Towne1, J E Sims

  • 1Inflammation Research, Amgen Inc., Seattle, WA 98119, United States.

Current Opinion in Pharmacology
|March 9, 2012
PubMed
Summary
This summary is machine-generated.

Interleukin-36 (IL-36) plays a critical role in psoriasis, a severe skin condition. Targeting IL-36 can reduce skin inflammation, offering potential therapeutic strategies for psoriasis patients.

Related Experiment Videos

Last Updated: May 24, 2026

Lymphocyte Isolation from Human Skin for Phenotypic Analysis and Ex Vivo Cell Culture
10:31

Lymphocyte Isolation from Human Skin for Phenotypic Analysis and Ex Vivo Cell Culture

Published on: April 8, 2016

Area of Science:

  • Dermatology
  • Immunology
  • Molecular Biology

Background:

  • Psoriasis is a prevalent skin disease with substantial physical and psychological impacts.
  • Emerging evidence highlights the significant role of Interleukin-36 (IL-36) in the pathogenesis of psoriasis.

Purpose of the Study:

  • To elucidate the specific role of IL-36 in the development and exacerbation of psoriasis.
  • To investigate the therapeutic potential of modulating IL-36 signaling pathways in psoriatic skin.

Main Methods:

  • Utilized mouse models with IL-36 overexpression to mimic human plaque psoriasis.
  • Assessed the effects of IL-36 inhibition on inflammation in human psoriatic skin samples.
  • Examined the consequences of Interleukin-36 receptor antagonist (IL-36Ra) deficiency in skin disease models.

Main Results:

  • Overexpression of IL-36 in mouse skin induced a phenotype resembling human plaque psoriasis.
  • Inhibition of IL-36 effectively reduced inflammation in human psoriatic skin.
  • Loss of IL-36Ra led to a distinct and more severe pustular psoriasis phenotype.

Conclusions:

  • IL-36 is a key mediator in the inflammatory processes of psoriasis.
  • Modulating IL-36 activity presents a promising therapeutic avenue for managing psoriasis.
  • IL-36 influences both immune cells and skin components like keratinocytes and fibroblasts in psoriasis.